-Loaded with catalyst next 12 months, 5 P2 readouts all orphin indications. -Cash 45M est, call is Q3-18 -Market Cap 64M -low floater 8m shares -institutions owns 70%
-Defined catalyst date for PAH, 4 billion market today. Company will have last patient visit in Ocotber for their P2 trial with "topline results at JPM Conference in 2nd week of January." $EIGR on my watch for Fall purchase as we get closer to several catalysts.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.